Newsletter Tool

Today's Rundown

EsoCap swallows up VC cash to fuel study of topical delivery to the esophagus
Closed-loop system offers promise of automated overdose therapy
Topical treatment for chemotherapy pain clears early clinical test, teeing up further study of alternative to oral options
Eli Lilly, under pressure from Biohaven, launches head-to-head migraine trial between Emgality and Nurtec
Merck pauses 'very important' HIV program after seeing red flag in phase 2 trial of once-weekly combo

Featured Story

EsoCap swallows up VC cash to fuel study of topical delivery to the esophagus

By Nick Paul Taylor

Investors have bet on EsoCap’s vision for the topical delivery of drugs to the esophagus. EsoCap, which recently entered phase 2, will use the money to scale up and explore the use of its platform in additional indications.

Closed-loop system offers promise of automated overdose therapy

By Nick Paul Taylor

The need to quickly administer naloxone to counter opioid overdoses has spurred innovation in drug delivery for years, with intramuscular, subcutaneous and nasal doses all used, but the approaches all rely on there being someone present to administer the countermeasure. Recognizing that limitation, a team at the University of Washington has developed an automated naloxone delivery system.

Topical treatment for chemotherapy pain clears early clinical test, teeing up further study of alternative to oral options

By Nick Paul Taylor

AlgoTherapeutix is advancing its plan to unlock the power of amitriptyline through topical delivery. With the phase 1 trial meeting its objectives, AlgoTherapeutix is now gearing up for a pivotal study in chemotherapy-induced peripheral neuropathy.

Eli Lilly, under pressure from Biohaven, launches head-to-head migraine trial between Emgality and Nurtec

By Angus Liu

As Biohaven’s fast-growing Nurtec ODT pressures rival migraine prevention medicines, one injectable player decided to bring the fight to the oral drug with a head-to-head clinical trial.

Merck pauses 'very important' HIV program after seeing red flag in phase 2 trial of once-weekly combo

By Nick Paul Taylor

A “very important” part of Merck’s HIV strategy has come off the rails. Just months after talking up the importance of MK-8507, Merck has paused development of the asset in response to midphase data that also raised questions about the backbone of all the company’s planned HIV regimens.